中国麻风皮肤病杂志 ›› 2023, Vol. 39 ›› Issue (10): 713-715.doi: 10.12144/zgmfskin202310713

• 论著 • 上一篇    下一篇

IL-5介导甲磺酸伊马替尼诱发的红皮病型药疹一例并文献复习

王田宇,鲁阳,孙乐乐,孙勇虎   

  1. 山东第一医科大学附属皮肤病医院(山东省皮肤病医院),山东省皮肤病性病防治研究所,山东济南,250022
  • 出版日期:2023-10-15 发布日期:2023-10-11

Erythrodermic drug eruption induced by IL-5-mediated imatinib mesylate and literature review

WANG Tianyu, LU Yang, SUN Lele, SUN Yonghu   

  1. Shandong Provincial Hospital for Skin Diseases ＆ Shandong Provincial Institute of Dermatology and Venereology，Shandong First Medical University ＆ Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2023-10-15 Published:2023-10-11

PDF (PC)

112

摘要： 报道一例胃间质瘤患者服用甲磺酸伊马替尼7个月后全身泛发红斑脱屑、眶周水肿、指甲甲板增厚色沉等红皮病样表现，给予环孢素口服，2周后皮损好转，检测其治疗前后12项免疫因子发现IL-1β、IL-5及IFN-γ显著下降，其中IL-5从治疗前1811 pg/mL降至36.22 pg/mL,表明IL-5在甲磺酸伊马替尼诱发不良反应中发挥重要作用，提示靶向IL-5的生物制剂可能是治疗该病的潜在药物。

关键词: 甲磺酸伊马替尼, 红皮病型药疹, IL-5

Abstract: We reported a case of a patient with gastric stromal tumor who presented with  generalized erythematous desquamation, periorbital edema, and thickened, discolored nail plates after 7 months of treatment with imatinib mesylate. The patient was given oral cyclosporine, and the lesions subsided after 2 weeks. Analysis of 12 cytokines before and after treatment revealed a significant decrease in IL-1β, IL-5, and IFN-γ. Particularly, IL-5 decreased from 1811 pg/mL before treatment to 36.22 pg/mL, suggesting an important role of IL-5 in the adverse reactions induced by imatinib mesylate. This finding suggests that biologics targeting IL-5 may be potential drugs to treat the disease.

Key words: imatinib mesylate, erythrodermic drug eruption, IL-5